Home page

Huierkangxin has been selected for the 2024 Jiangsu Province Innovative Pharmaceutical Equipment Special Award List!

2024-03-08

Author: Internet

Selected on the list

Recently, the 2024 Jiangsu Province Manufacturing Strong Province Construction Special Fund Innovation Pharmaceutical Equipment Award Project List was released, and Ab&B Bio Tech CO., LTD. JS's independently developed Class I new drug quadrivalent influenza virus subunit vaccine (Huierkangxin) was selected for the 2023 approved innovative drug list.

About Huier Kangxin

Huierkangxin is a Class 1 new drug for preventive biological products. With its unique influenza virus subunit extraction technology, it not only ensures the high purity of HA and NA of the four vaccine strains and vaccine safety, but also demonstrates good immunogenicity. Multiple quality standards of the product are higher than those of China and the European Union Pharmacopoeia, filling the domestic gap!

More news

Recently, the Pharmaceutical High tech Zone (Gaogang District) awarded An Youcai, Chairman and General Manager of Ab&B Bio, the honorary title of "Top Ten Star Entrepreneurs" at the conference to promote entrepreneurial spirit and promote new industrialization! We fully recognize the spirit of Mr. An and Ab&B Bio in the development and industrialization of innovative vaccines for human use, which are daring to take risks and pioneering!

Further advances in orthopoxvirus mRNA vaccines

Nationally recognized!

06-30

2026

The world's first! The monkeypox mRNA vaccine has obtained dual clinical trial approvals from both China and the United States.

Recently, the IND application for a Class 1 new drug, the "Monkeypox mRNA vaccine," jointly submitted by Ab&B Bio-Tech CO.,LTD.JS (Ab&B Bio) and its subsidiary Yither Biotech CO., Ltd (Yither Bio), was approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration.

05-08

2026

The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating.

Recently, the IND application for a Class 1 new drug— "Respiratory Syncytial Virus mRNA Vaccine" —jointly submitted by Ab&B Bio-Tech Co. Ltd. JS (Ab&B Bio) and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) was approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration.

03-13

2026

Ab&B Bio-Tech Co., Ltd. collaborates with Walvax Biotechnology Co., Ltd. to seamlessly connect the third-generation subunit influenza vaccine and embark on a new journey of going global

On March 13, 2026, Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) and its parent company Ab&B Bio Tech Co., Ltd. (Ab&B Bio) officially signed a strategic cooperation agreement for the overseas market of influenza virus subunit vaccines with Watson Biotech Hong Kong Limited (hereinafter referred to as "Watson Hong Kong") in Taizhou. Both parties announced that they will jointly promote Ab&B Bio's independently developed influenza virus subunit vaccine to set sail overseas. This is not only a milestone moment for Chinese vaccine companies to cooperate and build a healthy industry ecosystem, but also signifies that China will bring safer and more effective solutions to the global influenza prevention and control field.

Customer Message

You can leave us your needs or suggestions, and we will reply to you as soon as we receive them.

Need more help?

Yither Biotech is striving for and committed to producing innovative and quality vaccines to contribute to the development of China’s biomedical industry and the wellness of Chinese and people around the world.

Online Message

CONTACT

E-Mail:
yue.peng@yitherbiotech.com
Hotline:
+86-021-61639751
Address:
No. 5, Lane 1690, zhangheng Road, Pudong New Area, Shanghai

QUICK LINKS

Home
Product
About us
News
Contact

PRODUCTS

Listed products
Products under development

Business license